Pasithea Therapeutics Corp. (KTTAW) EBITDA (2021 - 2026)

Pasithea Therapeutics has disclosed EBITDA across 6 years of filings, most recently posting -$5.7 million for Q2 2026.

• In Q2 2026, EBITDA fell 49.92% year-over-year to -$5.7 million; the TTM figure through Jun 2026 stood at -$24.0 million (down 74.16% YoY), while the FY2025 annual figure was -$20.9 million, down 46.37% from the prior year.
• EBITDA came in at -$5.7 million for Q2 2026 at Pasithea Therapeutics, down from -$4.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$2.4 million in Q1 2022 to a low of -$10.3 million in Q4 2025.
• Average EBITDA over 5 years is -$4.2 million, with a median of -$3.8 million recorded in 2023.
• Year-over-year, EBITDA slumped 337.5% in 2022 and jumped 36.69% in 2024.
• Over 5 years, EBITDA stood at -$5.1 million in 2022, then dropped by 1.34% to -$5.1 million in 2023, then jumped by 36.69% to -$3.3 million in 2024, then slumped by 214.65% to -$10.3 million in 2025, then surged by 44.29% to -$5.7 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$5.7 million in Q2 2026, -$4.9 million in Q1 2026, and -$10.3 million in Q4 2025.